These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 2124530)

  • 41. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review.
    Roekevisch E; Spuls PI; Kuester D; Limpens J; Schmitt J
    J Allergy Clin Immunol; 2014 Feb; 133(2):429-38. PubMed ID: 24269258
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adjunctive therapy with interferon-gamma for the treatment of pulmonary tuberculosis: a systematic review.
    Gao XF; Yang ZW; Li J
    Int J Infect Dis; 2011 Sep; 15(9):e594-600. PubMed ID: 21715206
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of systemic sclerosis.
    Wigley FM
    Curr Opin Rheumatol; 1992 Dec; 4(6):878-86. PubMed ID: 1457284
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Clinical efficacy and safety of long-term immunomodulating therapy with interferon beta].
    Demina TL; Khachanova NV; Davydovskaia MV; Popova NF; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(4):24-6. PubMed ID: 18567192
    [No Abstract]   [Full Text] [Related]  

  • 45. Emerging drugs for the treatment of uveitis.
    Leung TG; Thorne JE
    Expert Opin Emerg Drugs; 2013 Dec; 18(4):513-21. PubMed ID: 24274613
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of refractory Whipple disease with interferon-gamma.
    Schneider T; Stallmach A; von Herbay A; Marth T; Strober W; Zeitz M
    Ann Intern Med; 1998 Dec; 129(11):875-7. PubMed ID: 9867729
    [No Abstract]   [Full Text] [Related]  

  • 47. Current disease-modifying therapies in multiple sclerosis.
    Kieseier BC; Hartung HP
    Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Systemic sclerosis: hypothesis-driven treatment strategies.
    Charles C; Clements P; Furst DE
    Lancet; 2006 May; 367(9523):1683-91. PubMed ID: 16714190
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Systemic scleroderma. Multicenter trial of 1 year of treatment with recombinant interferon gamma.
    Hunzelmann N; Anders S; Fierlbeck G; Hein R; Herrmann K; Albrecht M; Bell S; Thur J; Muche R; Adelmann-Grill B; Wehner-Caroli J; Gaus W; Krieg T
    Arch Dermatol; 1997 May; 133(5):609-13. PubMed ID: 9158414
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Combination antimetabolite-alkylating agent-vinblastine in the treatment of advanced breast cancer].
    Pipino G; Germiniani R; Lavorato F
    Minerva Med; 1977 Mar; 68(13):835-7. PubMed ID: 321990
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Skin collagen from scleroderma patients before and after cyclosporin A treatment.
    Francès C; Branchet MC; Blétry O; Lefevre C; Boisnic S; Kern P; Godeau P
    Clin Exp Dermatol; 1988 Jan; 13(1):1-3. PubMed ID: 3208433
    [No Abstract]   [Full Text] [Related]  

  • 52. Cyclosporine: therapeutic effects in rheumatic diseases.
    Amor B; Dougados M
    Transplant Proc; 1988 Jun; 20(3 Suppl 4):218-23. PubMed ID: 3289207
    [No Abstract]   [Full Text] [Related]  

  • 53. [Current treatment of systemic sclerosis. Part II. Vascular and antifibrotic treatment].
    Sicińska J; Rudnicka L
    Pol Merkur Lekarski; 2008 Aug; 25(146):196-200. PubMed ID: 18942347
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cyclosporine in the treatment of an unusual case of juvenile systemic sclerosis.
    al-Mayouf SM; Silverman ED; Feldman BM; Thorner P; Laxer RM
    J Rheumatol; 1998 Apr; 25(4):791-3. PubMed ID: 9558187
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunotherapy in multiple sclerosis, Part 2.
    Becker CC; Gidal BE; Fleming JO
    Am J Health Syst Pharm; 1995 Oct; 52(19):2105-20; quiz 2132-4. PubMed ID: 8535945
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Systemic therapy of atopic dermatitis in children and adults.
    Simon D
    Curr Probl Dermatol; 2011; 41():156-164. PubMed ID: 21576956
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cyclosporine and multiple sclerosis: the cons.
    Rudge P
    Neurology; 1988 Jul; 38(7 Suppl 2):29-30. PubMed ID: 3290712
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A short story of anti-rheumatic therapy. VIII. The immunodepressants.
    Pasero G; Marson P
    Reumatismo; 2012 Mar; 64(1):44-54. PubMed ID: 22472783
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Prospects in the treatment of rheumatoid polyarthritis].
    Crouzet J
    Rev Rhum Mal Osteoartic; 1988 Apr; 55(6):472-4. PubMed ID: 3134690
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Selected issues of immunomodulating treatment in multiple sclerosis].
    Cendrowski W
    Neurol Neurochir Pol; 2004; 38(4):299-306. PubMed ID: 15383958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.